Antineoplastic Agents, Immunological

"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000074322
MeSH Number(s)	D27.505.954.248.384
Concept/Terms	Antineoplastic Agents, Immunological Antineoplastic Agents, Immunological Immunological Antineoplastic Agents Antineoplastics, Monoclonal Antibodies Antineoplastics, Monoclonal Antibodies Antibodies Antineoplastics, Monoclonal Monoclonal Antibodies Antineoplastics Monoclonal Antibodies, Antineoplastic Antineoplastic Monoclonal Antibodies Antineoplastic MAbs Antineoplastics, Monoclonal Antibody Monoclonal Antibody Antineoplastics MAbs, Antineoplastic

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Immunological [D27.505.954.248.384]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Immunological".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.

Bar chart showing 21 publications over 4 distinct years, with a maximum of 13 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2017	3	1	4
2018	11	2	13
2019	2	0	2
2020	2	0	2

Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.

Rischin D, Gil-Martin M, González-Martin A, Braña I, Hou JY, Cho D, Falchook GS, Formenti S, Jabbour S, Moore K, Naing A, Papadopoulos KP, Baranda J, Fury W, Feng M, Stankevich E, Li J, Yama-Dang NA, Yoo SY, Lowy I, Mathias M, Fury MG. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 11; 159(2):322-328.

View in: PubMed
Zamarin D, Burger RA, Sill MW, Powell DJ, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol. 2020 06 01; 38(16):1814-1823.

View in: PubMed
Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.

View in: PubMed
Khreis TJ, Azar IH, Patel R, Mehdi SA. Durvalumab-Induced Hyperprogressive Disease in Nonmetastatic Lung Cancer. J Oncol Pract. 2019 04; 15(4):217-219.

View in: PubMed
Tripathi A, Plimack ER. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Curr Urol Rep. 2018 Nov 07; 19(12):109.

View in: PubMed
Baxley AA, Doyin-Lipede OA, Razaq MA. Hypersensitivity to Cetuximab After Geographic Relocation. Am J Ther. 2018 Nov/Dec; 25(6):e699-e700.

View in: PubMed
Mukherjee S, Ibrahimi S, Machiorlatti M, Roman D, Saleem R, Hassan A, Baxley A, Vesely S, Aljumaily R. Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. Am J Ther. 2018 Nov/Dec; 25(6):e767-e768.

View in: PubMed
Mukherjee S, Ibrahimi S, Aljumaily R, Cherry M. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome. Am J Ther. 2018 Nov/Dec; 25(6):e711-e712.

View in: PubMed
Richardson DL, Seward SM, Moore KN. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):1057-1071.

View in: PubMed
Dai Q, Wilhelm S, Ding D, Syed AM, Sindhwani S, Zhang Y, Chen YY, MacMillan P, Chan WCW. Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors. ACS Nano. 2018 08 28; 12(8):8423-8435.

View in: PubMed

People

Explore

Similar Concepts

Top Journals